

Athena Announces the Establishment of a New Pharmaceutical Manufacturing Plant in India with a €10 Million Investment

23 September 2024 :

Athena Drug Delivery Solutions Private. Ltd a subsidiary of Athena Pharmaceutiques SA France, a leading innovator in the pharmaceutical industry, is thrilled to announce the establishment of a new state-of-the-art pharmaceutical manufacturing plant in Maharashtra, India. This significant development is backed by a €10 million investment and is set to transform the company's production capabilities and support our clients world-wide in the launches of their products based on Athena's dossiers.

The new facility, located close to its existing manufacturing plant in Ambarnath, Maharashtra, India, will serve for both local and export to highly regulated markets such as Europe, Canada, Brazil, Russia, South Africa and many Pharmemerging markets.

The establishment of the new plant is expected to create 300 new jobs in the region, spanning a range of roles from skilled manufacturing positions to research and development opportunities.

Mr. Alexandre Williams, President and Mr. Mahendra Chaudhari, Managing Director, , said, "We are incredibly excited about the establishment of our new manufacturing plant," This investment not only enhances our production capabilities but also reflects our commitment to our clients . . The facility will commence operations in mid-2026 marking a new chapter in Athena Pharmaceutiques ongoing growth and innovation journey.

About Athena :

Athena is engaged in Licensing and Development model supported by its Manufacturing facilities and R&D Centre in France and India approved by EU GMP, Brazil, Canada, Russia, KSA, China and many others Pharmemerging markets. Athena's 450 Specialized Staff are focus on value added products for mature and emerging markets.

Athena provides product lifecycle management solutions for Oral Solids based on its proprietary technology's platforms viz., Acetyl Cysteine Stick w/wo water, Bisoprolol Aspirin, Bilastine ODT, Etifoxine, Fenofibrate, Levoceterizine ODT, Ketorolac Sublingual, Ketoprofen-Omeprazole, Lisdexamphetamine ODT, Mesalazine High Dose Sachets, Ondansetron ODT, Paracetamol Effervescent Tablet, Secnidazole High Dose Sachet, Racecadotril Sachets, Tramadol +Paracetamol ODT and Zolpidem ODT and Sublingual. These products are already marketed by leading companies across geographies or are under registration.